Q3 2026 Aug 9, 2026

Embecta's shares surged 26.3% following Q3 results, driven primarily by the market’s positive reception of the Owen Mumford acquisition and the expanded addressable market it creates, overshadowing reported revenue decline and ongoing challenges in the legacy business.

Key takeaways

Total revenue declined 8.1% year-over-year on an as-reported basis and 8.9% on an adjusted constant currency basis.
Sequential improvements included approximately $50 million revenue increase and a $21 million rise in adjusted operating income versus Q2.
Acquisition of Owen Mumford closed mid-quarter, adding new product lines such as the Aidaptus auto-injector platform and pharmaceutical services, significantly broadening market exposure beyond insulin injection devices.
The combined manufacturing footprint expanded with four new sites, supporting potential future operational optimization and emerging market growth.
Over 90% of revenue now arises from products under the Embecta brand following successful brand transitions in key international markets.

Q2 2026 May 6, 2026

Embecta shares plummeted 61.5% following a disappointing quarter marked by a sharp revenue decline and a significant guidance cut driven primarily by share losses and volume softness in its core pen needle category.

Key takeaways

Q2 revenues dropped 14.4% year-over-year on an as-reported basis and 17.4% on an adjusted constant currency basis, missing expectations.
U.S. revenue shortfall dominated by approximately $25 million in market share loss and $20 million from overall market volume weakness in pen needles.
Additional $8 million in pen needle revenue headwinds from inventory reduction and pricing pressure; syringe sales also down by $13 million, largely due to reduced use of compounded drugs.
Alcohol swab product discontinuation contributed approximately $5 million to the revenue decline, following supplier issues.
Full-year 2026 revenue guidance slashed from $1.071–1.093 billion to $1.015–1.035 billion, reflecting ongoing U.S. challenges despite steady international performance.

Q1 2026 Feb 5, 2026

Embecta Corp. reported stable revenues in Q1 2026 while successfully transitioning its brand and laying the groundwork for future growth in chronic care and drug delivery markets.

Key takeaways

Completed the stand-up phase, operationalizing independent systems while maintaining stable constant currency revenue.
Over 95% of products in the U.S. and Canada have transitioned to the Embecta brand, with global rollout expected by the end of 2026.
Secured exclusive access with an additional Medicare Part D payer and renewed contracts with leading payers, enhancing competitive positioning.
Progressing towards product launches in the pen needle and syringe market, with manufacturing validation underway for market-appropriate offerings.
Collaboration with over 30 pharmaceutical partners on co-packaging pen needles with GLP-1 therapies, with initial launches anticipated in 2026.

Embecta Corp. Common Stock Earnings Recaps

Keep exploring